HC Wainwright & Co. Upgrades NovoCure to Buy, Raises Price Target to $30

Benzinga · 10/16 10:13
HC Wainwright & Co. analyst Emily Bodnar upgrades NovoCure (NASDAQ:NVCR) from Neutral to Buy and raises the price target from $24 to $30.